• About
  • Masthead
  • License Content
  • Advertise
  • Press Releases
  • Newsroom
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

Sign in
SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
Sign in
SUBSCRIBE
2 Minute Medicine
Sign in
Subscribe
2 Minute MedicineFree on Google PlayGet
✦EvidencePulse™by 2 Minute Medicine3 reportsYou askedtop stroke trials 2026Synthesizing medical evidence...Top 2026 stroke trial results:OCEANIC — ischemic stroke: 6.2% vs 8.4%OPTION* — mRS 0–1: 43.6% vs 34.2%ORIENTAL* — mRS 0–2: 58.6% vs 46.6%*Higher sICH in intervention armsParticipants randomizedNOCEANIC12,327OPTION570ORIENTAL564Ask about guidelines or landmark trials...↑Try EvidencePulse™Ask the evidence. Get the signal.Try it now →
Home All Specialties Oncology

Systemic Therapy and Stereotactic Body Radiotherapy in Oligoprogressive Breast Cancer or Lung Cancer

byDaniel GoldshteinandSze Wah Samuel Chan
January 8, 2024
in Chronic Disease, Oncology
Reading Time: 3 mins read
Radiation therapy collage: an older woman in a calm portrait beside the curved arm of a treatment machine and a mesh mask
Share on FacebookShare on TwitterShare on LinkedIn

1. Progression-free survival in NSCLC was found to be significant with HR 0.41 compared to breast cancer which was non-significant with HR 0.78.

2. Grade 2 or worse adverse events occurred 41% in the standard-of-care group vs 62% in the SBRT group.

Evidence Rating Level: 1 (Excellent)

Study Rundown: The treatment paradigm for metastatic cancer involves systemic therapies, but interest has grown in using ablative radiotherapy for oligometastatic disease (limited number of metastatic sites). Recent studies have shown some improved survival with stereotactic ablative radiotherapy (SBRT), however the efficacy remains unclear, prompting a randomized, prospective, phase 2 study focusing on breast cancer and NSCLC to assess the benefits of ablative radiotherapy for oligoprogressive metastatic cancer. The primary endpoint was progression-free survival (PFS) and secondary outcomes included overall survival (OS), safety, and quality of life (QoL). Median PFS was 3.2 months in the standard-of-care group versus 7.2 months in the SBRT group, with an HR 0.53 (p=0.0035). There was more benefit found in patients with NSCLC (HR 0.41, p=0.0039) than with breast cancer (HR 0.78, p=0.43). Median OS was similar across both groups with an HR 0.99, p=0.40), and remained similar in disease-specific subgroups. The SBRT group remained on the current systemic therapy for 8.1 months vs standard-of-care group which was 5.3 months (p=0.014). The time to initiation of a new therapy was 11.0 months for NSCLC vs 3.9 months for breast cancer (p=0.0030). An exploratory analysis was done with changes in the mutant allele fraction and cell-free DNA content in blood samples, which correlate to disease burden. It was found that in the NSCLC cohort, the SBRT group had a significant decrease in median allele fraction between baseline and follow-up (p=0.022), whereas those in the standard-of-care group had no significant change (p=0.11). There was no change seen in either group for the breast cancer cohort. With regards to safety, grade 2 or worse adverse events occurred in 41% of the standard-of-care group vs 62% in the SBRT group, with the most common toxicities being decreased lymphocyte count, anemia, and decreased neutrophil count. QoL scores were similar between patients in the standard-of-care and SBRT groups. The strengths of this study included the study design as well as exploratory analysis, and the limitations include histological heterogeneity and allowing variable systemic therapy options. Overall, it was found that SBRT in addition to standard-of-care treatment had improved endpoints for patients with NSCLC but had no significant benefit to those with breast cancer.

Click to read the study in The Lancet

Relevant Reading: Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial

RELATED REPORTS

Stereotactic body radiotherapy is noninferior to hypofractionated radiotherapy for localized prostate cancer

Radiotherapy with cetuximab or durvalumab for advanced HNSCC

FDA approvedFor breast cancer: Etcamah (camizestrant), Sep 4, 2026→

In-Depth [randomized controlled trial]: This phase 2, open label trial enrolled adults with oligoprogressive (up to 5 extracranial individual lesion) metastatic breast cancer or NSCLC who have progressed on first-line systemic therapy and randomized them into two groups; SBRT and standard-of-care (SBRT group, 55 patients) vs standard of care without SBRT (standard-of-care group, 51 patients). The standard of care and radiotherapy dose was determined as per physician’s discretion, but regimens for RT ranged from 27–30 Gy in three fractions to 30–50 Gy in five fractions. Median PFS was 3.2 months (95%CI, 2.0-4.5) in the standard-of-care group versus 7.2 months (4.5-10.0) in the SBRT group, with an HR 0.53 (95%CI, 0.35-0.81, p=0.0035). There was more benefit found in patients with NSCLC (HR 0.41, 95%CI, 0.22-0.75, p=0.0039) than with breast cancer (HR 0.78, 95%CI 0.43-1.43, p=0.43). Median OS was similar across both groups with an HR 0.99, 95%CI, 0.55-1.81, p=0.40), and remained similar in disease-specific subgroups. The SBRT group remained on the current systemic therapy for 8.1 months (95%CI, 5.1-15.0) vs standard-of-care group which was 5.3 months (3.0-7.6, p=0.014). The time to initiation of a new therapy was 11.0 months for NSCLC (95%CI, 5.8-NA) vs 3.9 months in breast cancer (2.6-6.3, p=0.0030). An exploratory analysis was done with changes in the mutant allele fraction and cell-free DNA content in blood samples, which correlate to disease burden. It was found that in the NSCLC cohort, the SBRT group had a significant decrease in median allele fraction between baseline and follow-up (p=0.022), whereas those in the standard-of-care group had no significant change (p=0.11). There was no change seen in either group for the breast cancer cohort. With regards to safety, grade 2 or worse adverse events occurred in 41% of the standard-of-care group vs 62% in the SBRT group, with the most common toxicities being decreased lymphocyte count (40% in the SBRT group vs 20% in the standard-of-care group), anemia (29% vs 12%), and decreased neutrophil count (22% vs 12%). QoL scores were similar between patients in the standard-of-care and SBRT groups. Overall, it was found that SBRT in addition to standard-of-care treatment had improved endpoints for patients with NSCLC but had no significant benefit to those with breast cancer.

Image: PD

©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: oligometastatic cancerRadiation Therapystereotactic body radiotherapy
Previous Post

Doxycycline post-exposure prophylaxis ineffective for sexually transmitted infections in women

Next Post

Perioperative pembrolizumab with chemotherapy for gastric and gastroesophageal junction adenocarcinoma improves pathological complete response rate compared with placebo

RelatedReports

Chronic Disease

Stereotactic body radiotherapy is noninferior to hypofractionated radiotherapy for localized prostate cancer

November 22, 2024
Parathyroid cancer collage: the back of a thyroid with four small parathyroid glands, a blood tube, a bone and a woman
Chronic Disease

Radiotherapy with cetuximab or durvalumab for advanced HNSCC

November 18, 2024
2 Minute Medicine

Machine learning algorithm shows limited capacity for reducing health spending for radiation therapy outpatients

November 25, 2024
#VisualAbstract: Five-Fraction Stereotactic Body Radiotherapy was Noninferior to Control Radiotherapy in Biochemical or Clinical Failure in Localized Prostate Cancer
StudyGraphics

#VisualAbstract: Five-Fraction Stereotactic Body Radiotherapy was Noninferior to Control Radiotherapy in Biochemical or Clinical Failure in Localized Prostate Cancer

October 30, 2024
Next Post

Perioperative pembrolizumab with chemotherapy for gastric and gastroesophageal junction adenocarcinoma improves pathological complete response rate compared with placebo

Novel coronavirus identified from patients with pneumonia in Wuhan, China

Characterization of demographics for those with post COVID-19 condition in Malaysia during Omicron wave

The Scan by 2 Minute Medicine®:  Ultra-Trail du Mont-Blanc, Taylor Swift, NBA rookie Chet Holmgren and Magic Mushrooms!

The Scan by 2 Minute Medicine®: Attacking Allergies, Shedding Light on Lung Cancer, New Year New Goals and Unoriginal Ozempic

✦ EvidencePulse™ by 2 Minute Medicine 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Removing Race and Ethnicity From Dialysis Mortality Risk Adjustment Changes Facility Performance Rankings
  • AI Model Shows Promise in Predicting PTSD Risk Following Trauma
  • 2 Minute Medicine Rewind November 16, 2026
License Content
Terms of Use | Disclaimer
Cookie Policy

Get the app

Read 2 Minute Medicine on iPhone, iPad and Android.

Download on the App StoreGet it on Google Play
QR code for www.2minutemedicine.com/app
On a computer? Scan this with your phone’s camera.
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ new physician-written study summaries monthly, 12,000+ searchable
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
  • ✓FDA drug approvals + clinical calculators

Already a member? Sign in

  • Get the app
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.